Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) Director Thomas Schall purchased 21,645 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was purchased at an average price of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director directly owned 74,530 shares of the company’s stock, valued at $348,055.10. This trade represents a 40.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Immuneering Stock Up 1.5%

Shares of NASDAQ IMRX opened at $4.85 on Thursday. Immuneering Corporation has a twelve month low of $1.10 and a twelve month high of $10.08. The firm has a market cap of $313.16 million, a PE ratio of -2.72 and a beta of 0.48. The business has a fifty day simple moving average of $6.25 and a two-hundred day simple moving average of $5.83.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IMRX. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Immuneering in a research report on Thursday, November 13th. Leerink Partners began coverage on shares of Immuneering in a report on Friday, October 31st. They issued an “outperform” rating and a $15.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a report on Tuesday, September 30th. Oppenheimer lifted their price objective on shares of Immuneering from $21.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Finally, Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immuneering has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Institutional Trading of Immuneering

A number of institutional investors have recently bought and sold shares of IMRX. Iridian Asset Management LLC CT acquired a new position in shares of Immuneering in the 3rd quarter valued at $1,926,000. Flower City Capital acquired a new position in shares of Immuneering in the second quarter valued at about $108,000. Kingsview Wealth Management LLC purchased a new position in shares of Immuneering in the second quarter worth about $47,000. GSA Capital Partners LLP acquired a new stake in shares of Immuneering during the third quarter worth about $265,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Immuneering during the third quarter worth about $343,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.